[Explanation] On August 27, the reporter learned from a press conference held by the Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission that the "Hong Kong-Macao Medicines and Equipment Exchange" policy will be officially implemented in 9 cities in the Guangdong-Hong Kong-Macao Greater Bay Area. , Identified 5 first batch of designated medical institutions in the Mainland,
[Explanation] Su Shengfeng, a member of the Party Leadership Group of the Guangdong Provincial Drug Administration, said at the meeting that since the “Hong Kong-Macau Medicines and Devices” policy pilot was launched in the Shenzhen Hospital of the University of Hong Kong in January this year, 9 imported drugs and 2 medical devices have been approved for clinical urgent use. A total of 150 patients benefited.
The evaluation results of the pilot work organized by a third-party organization show that the pilot work of the "Hong Kong and Macao medicine and equipment exchange" policy has a basis that can be replicated and promoted.
[Concurrent] Su Shengfeng, Member of the Party Leadership Group of Guangdong Drug Administration
The evaluation results show that the pilot work organization and leadership mechanism is sound, the coordination department has clear responsibilities, the work flow is smooth and orderly, and the product safety risks are controllable. This will effectively promote the "homogenization" of medical quality in the Guangdong-Hong Kong-Macao Greater Bay Area and promote drugs in the Greater Bay Area. The innovative linkage of medical device R&D, production, and circulation has achieved the expected goals of the pilot.
[Explanation] It is understood that in mid-April this year, the first drug "Anti-D immunoglobulin injection" and the first medical device "Magnetic Controllable Extension Titanium Rod" imported through the "Hong Kong and Macao Medicines and Devices" policy were put into use in Hong Kong University Shenzhen Hospital use.
Ms. Yang, a pregnant woman who originally planned to go to Macau for injection, received an "anti-D immunoglobulin injection" in Shenzhen.
[Explanation] Zhou Zixiao, deputy director of the Guangdong Provincial Health Commission, said at the meeting that the pilot work has been completed and good results have been achieved. The experience gained in the pilot has been extended to other cities and designated medical institutions in the Greater Bay Area that meet the requirements.
[Concurrent] Zhou Zixiao, Deputy Director of Guangdong Provincial Health Commission
Based on medical technology and level, medical device management capabilities, application safety, and service area considerations, after research, our committee finally determined that pilot hospitals, Hong Kong and Macao wholly-owned, joint venture and cooperative medical institutions above level 2 will be the first batch of designated medical institutions in the Greater Bay Area. There are five in total.
There are two in Guangzhou and one in Shenzhen, Zhuhai and Zhongshan.
The five medical institutions are: The University of Hong Kong Shenzhen Hospital, Guangzhou Modern Hospital, Guangzhou United Family Hospital, Zhuhai Simalin Shunchao Eye Hospital, and Zhongshan Chen Xinghai Hospital.
[Explanation] At the meeting, the Guangdong Provincial Drug Administration issued a simplified registration and approval policy for traditional Chinese patent medicines that have been marketed in Hong Kong and Macau for external use, and the total approval time limit was reduced by half.
Qiu Nan, director of the Administrative Licensing Division of the Guangdong Provincial Drug Administration, said that the implementation of this policy will facilitate the entry of proprietary Chinese medicines for Hong Kong and Macao into the mainland market.
[Concurrent] Qiu Nan, Director of Administrative Licensing Division, Guangdong Drug Administration
Simplifying the implementation of registration approval (policy) will facilitate the entry of proprietary Chinese medicines for external use from Hong Kong and Macau into the mainland market, provide convenience for Hong Kong and Macau compatriots living and working in the mainland, and facilitate the purchase of Hong Kong and Macau medicines by residents in the Guangdong-Hong Kong-Macao Greater Bay Area who have the same medication habits.
Second, it is conducive to helping Hong Kong and Macao Chinese patent medicine companies to explore the mainland market and realize the common development of the Chinese medicine industry in the Guangdong-Hong Kong-Macao Greater Bay Area.
[Explanation] The expansion of "Hong Kong and Macao Medicine and Xiatong", the relaxation of proprietary Chinese medicines for external use in Hong Kong and Macao.
The "homogenization" of medical quality in the Guangdong-Hong Kong-Macao Greater Bay Area is accelerating.
(Reported by reporter He Junjie and Cai Minjie from Guangzhou)
Editor in charge: [Ji Xiang]